Sugi Predict

Sugi Predict / Compounds / SCHEMBL519418

SCHEMBL519418

SCHEMBL519418

O=[N+]([O-])c1ccc(OCc2ccccc2)cc1F

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 3/20 0.61
▸ ATM Q13315 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ AR P10275 1/20 0.53
▸ BACE1 P56817 1/20 0.52
▸ CTSV O60911 3/20 0.49
▸ CTSL P07711 3/20 0.49
▸ MAOB P27338 2/20 0.49
▸ TLR4 O00206 1/20 0.49
▸ TLR2 O60603 1/20 0.49
▸ MAOA P21397 1/20 0.49
▸ ALOX5 P09917 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAPGEF3 O95398 1/20 0.46
▸ PIN1 Q13526 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463874 1.00 PTGES (0.61) PTGESATMMEN1NPC1RAB9A
SCHEMBL2022545 0.88 PTGES (0.61) PTGESATMMEN1NPC1RAB9A
SCHEMBL29503061 0.88 PTGES (0.61) PTGESATMMEN1NPC1RAB9A
SCHEMBL1578696 0.88 ATM (0.56) PTGESATMMEN1KMT2AMAOB
SCHEMBL3363943 0.87 MAOB (0.57) ATMMAOBMAOATDP1
SCHEMBL30152219 0.87 MAOB (0.57) ATMMAOBMAOATDP1
SCHEMBL30832846 0.86 MEN1 (0.57) PTGESATMMEN1NPC1RAB9A
SCHEMBL1663438 0.86 MEN1 (0.57) PTGESATMMEN1NPC1RAB9A
SCHEMBL9114209 0.86 MAOB (0.56) PTGESATMMAOBTLR4TLR2
SCHEMBL572373 0.86 PTGES (0.55) PTGESATMMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
US-20250026722-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Université Côte d’Azur (FR) 2025-01-23 — — US disclosed
CN-115322199-B Compounds and their use in the treatment of schistosomiasis 默克专利股份有限公司 2024-12-10 — — CN disclosed
CN-118684667-A Compounds for the treatment of fasciolopsis 默克专利股份有限公司 2024-09-24 — — CN disclosed
US-12060355-B2 Compounds for use in the treatment of fascioliasis MERCK PATENT GMBH (DE) 2024-08-13 — — US disclosed
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
EP-4399202-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2024-07-17 — — EP disclosed
CN-112512636-B Compounds for the treatment of fasciolopsis 默克专利股份有限公司 2024-06-18 — — CN disclosed
CN-117466897-A Highly selective FGFR2 inhibitors 深圳福沃药业有限公司 2024-01-30 — — CN disclosed
CN-110869360-B Phenylacetamides as ROCK inhibitors 百时美施贵宝公司 2023-12-15 — — CN disclosed
EP-1341768-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS AstraZeneca AB (SE) 2003-09-10 — — EP disclosed
CN-1431999-A Indole derivatives with vascular damagine activity ASTRAZENECA AB (SE) 2003-07-23 — — CN disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 — — US disclosed
WO-2003037898-A1 PYRIMIDO [4,5-B] INDOLE DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-05-08 — — WO disclosed
EP-1289952-A1 INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY AstraZeneca AB (SE) 2003-03-12 — — EP disclosed
US-20020188124-A1 Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes MSD K.K. (JP) 2002-12-12 — — US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 — — WO disclosed
WO-2002046168-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS ASTRAZENECA AB (SE) 2002-06-13 — — WO disclosed
WO-2001092224-A1 INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY ASTRAZENECA AB (SE) 2001-12-06 — — WO disclosed
EP-1123918-A1 AROMATIC AMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME Takeda Chemical Industries, Ltd. (JP) 2001-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026722-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS NFKBIA, IKBKG, IKBKB PTGES 1107/4885ATM 435/4885MEN1 1755/4885
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP PTGES 3527/4885ATM 4164/4885MEN1 2833/4885
US-20020188124-A1 Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes NPY1R, GPR119, NPY2R PTGES 1277/4885ATM 1971/4885MEN1 720/4885
US-12060355-B2 Compounds for use in the treatment of fascioliasis SLC10A1, SLC10A2, MGST3 PTGES 1098/4885ATM 4842/4885MEN1 3877/4885
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 PTGES 3719/4885ATM 3856/4885MEN1 1735/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C PTGES 3653/4885ATM 4145/4885MEN1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.